Ammar Hemaidan, MD
Gastroenterology · Port Orange, FLNPI 1033149752
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,550 of the $8,994 with a category attached, or 72.8%. Capsovision, Inc. accounts for 63.3% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $7,450 and has fallen 95.2% since, to $359 in 2025.
Across 65 payments — averaging $138.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Capsovision, Inc.$6K
- Capsopro Services LLC$1K
- AbbVie$537
- Johnson & Johnson$330
- Phathom Pharmaceuticals, Inc.$282
- Boston Scientific$235
- plus $720 from 10 others
Across 155 payments — averaging $3545.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$166K
- Bristol Myers Squibb$127K
- Gilead$120K
- AbbVie$50K
- Janssen Research & Development, LLC$49K
- Braintree Laboratories, Inc.$20K
- plus $18K from 4 others
What the payments were for
- Consulting fees$6,55073%
- Food & beverage$2,44427%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Capsovision, Inc. | 9 | $5,689 |
| Capsopro Services LLC | 1 | $1,200 |
| AbbVie(2 entities) | 21 | $537 |
| Johnson & Johnson(2 entities) | 9 | $330 |
| Phathom Pharmaceuticals, Inc. | 3 | $282 |
| Boston Scientific | 7 | $235 |
| Janssen Scientific Affairs, LLC | 2 | $224 |
| Pfizer | 4 | $155 |
| Olympus America Inc. | 1 | $111 |
| Ambu Inc. | 1 | $81 |
| Pentax Of America, Inc. | 1 | $44 |
| Intercept Pharmaceuticals, Inc. | 2 | $34 |
| Sanofi | 1 | $22 |
| Merck | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Bristol Myers Squibb | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$132
- STELARA$125
- Skyrizi$125
- LINX Reflux Management System$118
- VOQUEZNA$116
- EXALT Model D$116
- EVIS EXERA III COLONOVIDEOSCOPE$111
How this compares
$8,994 in reported general payments places this provider in the 80th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 69 | $1,179 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Port Orange
- Samuel GidayOrlando$2M
- Lukasz KwapiszMiami$1.2M
- Jennifer Seminerio-DiehlOrlando$1.1M
- Udayakumar NavaneethanSaint Petersburg$1.1M
- Ronen AraiCoral Springs$1.1M
- Charles SninskyGainesville$983K
- Peter DraganovGainesville$832K
- Arin NewmanMiami Beach$716K
- Joanna LopezMiami$670K
- Jose NietoSebring$573K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.